The stock of Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a huge mover today! About 1.27M shares traded hands. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has risen 20.39% since April 14, 2016 and is uptrending. It has outperformed by 15.70% the S&P500.
The move comes after 7 months negative chart setup for the $1.72B company. It was reported on Nov, 16 by Barchart.com. We have $12.14 PT which if reached, will make NASDAQ:HALO worth $103.20M less.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Ratings Coverage
Out of 6 analysts covering Halozyme Therapeutics (NASDAQ:HALO), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Halozyme Therapeutics has been the topic of 8 analyst reports since August 11, 2015 according to StockzIntelligence Inc. Piper Jaffray maintained the shares of HALO in a report on Friday, September 16 with “Overweight” rating. On Wednesday, March 9 the stock rating was maintained by JMP Securities with “Market Outperform”. Citigroup initiated the shares of HALO in a report on Wednesday, November 18 with “Buy” rating. The rating was initiated by Deutsche Bank with “Buy” on Thursday, November 3. On Tuesday, August 11 the stock rating was maintained by JMP Securities with “Market Outperform”. The firm earned “Outperform” rating on Friday, December 4 by Wells Fargo. The company was maintained on Wednesday, February 24 by Barclays Capital. The stock has “Overweight” rating given by Barclays Capital on Tuesday, September 22.
According to Zacks Investment Research, “Halozyme Therapeutics, Inc. is a therapeutically driven, development stage biopharmaceutical company dedicated to developing and commercializing recombinant human enzymes for the infertility, ophthalmology, and oncology communities. The company’s broad product development portfolio, including expected near- and long-term product offerings, is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company’s initial products are being developed to offer safer and purer alternatives toexisting slaughterhouse derived extracts that carry risks of pathogen contamination, immunogenicity, and toxicity. The commercialization of Halozyme’s highly versatile enzyme technology within proven markets will enable the company to positively impact the quality of medicine.”
Insitutional Activity: The institutional sentiment decreased to 1.04 in Q2 2016. Its down 0.29, from 1.33 in 2016Q1. The ratio dived, as 21 funds sold all Halozyme Therapeutics, Inc. shares owned while 46 reduced positions. 17 funds bought stakes while 53 increased positions. They now own 103.28 million shares or 2.86% more from 100.41 million shares in 2016Q1.
Third Security reported 19.31 million shares or 8.68% of all its holdings. Qs Investors Ltd holds 100,573 shares or 0.01% of its portfolio. The New York-based Metropolitan Life Insur Com Ny has invested 0% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Fiera Corp holds 0% of its portfolio in Halozyme Therapeutics, Inc. (NASDAQ:HALO) for 10,555 shares. Leisure Management has 30,053 shares for 0.29% of their US portfolio. Prudential Finance holds 0% of its portfolio in Halozyme Therapeutics, Inc. (NASDAQ:HALO) for 11,166 shares. Paradigm Cap Ny last reported 0.01% of its portfolio in the stock. The Delaware-based Blackrock Advisors Limited Company has invested 0% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Stephens Ar owns 11,000 shares or 0% of their US portfolio. Teacher Retirement Systems Of Texas, a Texas-based fund reported 15,269 shares. Moreover, Royal Bancorp Of Canada has 0% invested in Halozyme Therapeutics, Inc. (NASDAQ:HALO) for 14,200 shares. Raymond James And Associates has invested 0% of its portfolio in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Moreover, Carroll Financial Associates has 0% invested in Halozyme Therapeutics, Inc. (NASDAQ:HALO) for 1,000 shares. Guggenheim Limited reported 253,563 shares or 0.01% of all its holdings. Franklin Street Advsr Nc has 0.08% invested in the company for 50,000 shares.
More recent Halozyme Therapeutics, Inc. (NASDAQ:HALO) news were published by: Fool.com which released: “Why Did Halozyme Therapeutics, Inc. Plunge 29.5% in October?” on November 08, 2016. Also Seekingalpha.com published the news titled: “Halozyme Is A Core Biotech Buy” on November 15, 2016. Prnewswire.com‘s news article titled: “Halozyme Announces Broad Clinical Collaboration Agreement To Evaluate PEGPH20 …” with publication date: November 10, 2016 was also an interesting one.
HALO Company Profile
Halozyme Therapeutics, Inc., incorporated on August 23, 2007, is a biotechnology firm focused on developing and commercializing oncology therapies. The Firm operates in research, development and commercialization of enzymes segment. This segment also includes research and development, and bulk rHuPH20 manufacturing activities conducted under its collaborative agreements with third parties, and product sales of Hylenex recombinant. The Company’s research activities focus on human enzymes that alter the extracellular matrix and tumor microenvironment. The Company’s enzymes are used to facilitate the delivery of injected drugs and fluids. The Company’s rHuPH20 is the active ingredient in its commercially approved product, Hylenex recombinant, and it works by temporarily breaking down hyaluronan (HA), a naturally occurring complex carbohydrate that is a component of the extracellular matrix in tissues throughout the body, such as skin and cartilage. The Firm refers to the application the delivery of other drugs or fluids as its ENHANZE Technology. It licenses the ENHANZE Technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring injection through the subcutaneous route of administration.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.